Silexion TherapeuticsSLXN
13F holders, Q4 2024 (December 31)3holders
$2.00avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding Silexion Therapeutics Corp. (SLXN) in their 13F filings. The largest holders were Wildcat Capital Management, LLC ($228K), UBS Group AG ($30K) and HRT Financial LP ($23K).
- Company
- Silexion Therapeutics Corp.
- CUSIP
- G1281K122
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $281K |
| Exits | 0 | $0 |
Ownership 3 holders
| Wildcat Capital Management, LLC | 0.09% | New | 113,428 | $228K |
| UBS Group AG | 0.00% | New | 14,854 | $30K |
| HRT Financial LP | 0.00% | New | 11,887 | $23K |
"% of holder's portfolio" is SLXN's weight in each manager's 13F, not the share of Silexion Therapeutics Corp. the manager owns.